Clinical Applications of Comprehensive Genomic Profiling in Advanced Non-Small-Cell Lung Cancer-A Case Series

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2024 Jun 26

PMID 38920723

Authors

Chun-Ming Tsai

Chih-Hung Lin

Yu-Yen Chou

Hsiao-Yu Jen

Suyog Jain

Affiliations

Soon will be listed here.

Abstract

Background: Advanced non-small-cell lung cancer (NSCLC) can be treated with novel targeted therapies that are tailored to the genetic characteristics of malignancy. While tissue-based genomic testing is considered the gold standard for the detection of oncogenic driver mutations, several challenges like inadequate tissue availability, the invasiveness of procuring tumors, and prolonged turnaround time of analysis are encountered. Considering these limitations, guidelines have recognized liquid biopsies using circulating cell-free DNA (cfDNA) as a useful tool to complement conventional tissue testing. Even though cfDNA next-generation sequencing (NGS) can have high sensitivity and specificity, optimal patient benefit requires the interpretation of the molecular profiling results in the context of clinical and diagnostic features to achieve the best outcomes.

Case Descriptions: In this case series, we present six patients with advanced NSCLC whose plasma or tissue biopsy samples were analyzed with commercially available comprehensive NGS assays that elucidate the role of testing at various time points in the treatment journey. In all six cases, comprehensive genomic profiling (CGP) provided clinically useful information to guide treatment decisions.

Conclusion: Adding to the existing real-world evidence, this case series reinforces that CGP-driven treatment strategies in advanced NSCLC, coupled with other available clinical information, can optimize treatment decisions.

Citing Articles

Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions.

Garg P, Singhal S, Kulkarni P, Horne D, Malhotra J, Salgia R J Clin Med. 2024; 13(14).

PMID: 39064229 PMC: 11278207. DOI: 10.3390/jcm13144189.

References

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A . NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw. 2021; 19(3):254-266. DOI: 10.6004/jnccn.2021.0013. View

Jamal-Hanjani M, Wilson G, McGranahan N, Birkbak N, Watkins T, Veeriah S . Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 376(22):2109-2121. DOI: 10.1056/NEJMoa1616288. View

Paik P, Felip E, Veillon R, Sakai H, Cortot A, Garassino M . Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations. N Engl J Med. 2020; 383(10):931-943. PMC: 8422679. DOI: 10.1056/NEJMoa2004407. View

Leighl N, Page R, Raymond V, Daniel D, Divers S, Reckamp K . Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2019; 25(15):4691-4700. DOI: 10.1158/1078-0432.CCR-19-0624. View

Ahn B, Lee S, Lee J, Lee J, Hong M, Lim S . Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea. Cancer Treat Res Commun. 2023; 36:100715. DOI: 10.1016/j.ctarc.2023.100715. View

Keedy V, Temin S, Somerfield M, Beasley M, Johnson D, McShane L . American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011; 29(15):2121-7. DOI: 10.1200/JCO.2010.31.8923. View

Aggarwal C, Thompson J, Black T, Katz S, Fan R, Yee S . Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 5(2):173-180. PMC: 6396811. DOI: 10.1001/jamaoncol.2018.4305. View

Turner N, Kingston B, Kilburn L, Kernaghan S, Wardley A, Macpherson I . Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020; 21(10):1296-1308. PMC: 7599319. DOI: 10.1016/S1470-2045(20)30444-7. View

10.

Magbanua M, Swigart L, Ahmed Z, Sayaman R, Renner D, Kalashnikova E . Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023; 41(6):1091-1102.e4. PMC: 10330514. DOI: 10.1016/j.ccell.2023.04.008. View

11.

Burstein H, Krilov L, Aragon-Ching J, Baxter N, Chiorean E, Chow W . Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017; 35(12):1341-1367. DOI: 10.1200/JCO.2016.71.5292. View

12.

Lone S, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S . Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022; 21(1):79. PMC: 8932066. DOI: 10.1186/s12943-022-01543-7. View

13.

Schabath M, Welsh E, Fulp W, Chen L, Teer J, Thompson Z . Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2015; 35(24):3209-16. PMC: 4837098. DOI: 10.1038/onc.2015.375. View

14.

Luangdilok S, Wanchaijiraboon P, Chantranuwatana P, Teerapakpinyo C, Shuangshoti S, Sriuranpong V . Cyclin D1 expression as a potential prognostic factor in advanced -mutant non-small cell lung cancer. Transl Lung Cancer Res. 2020; 8(6):959-966. PMC: 6976362. DOI: 10.21037/tlcr.2019.12.01. View

15.

Choucair K, Mattar B, Van Truong Q, Koeneke T, Van Truong P, Dakhil C . Liquid Biopsy-based Precision Therapy in Patients with Advanced Solid Tumors: A Real-world Experience from a Community-based Oncology Practice. Oncologist. 2022; 27(3):183-190. PMC: 8914479. DOI: 10.1093/oncolo/oyac007. View

16.

Rolfo C, Mack P, Scagliotti G, Aggarwal C, Arcila M, Barlesi F . Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021; 16(10):1647-1662. DOI: 10.1016/j.jtho.2021.06.017. View

17.

Hong D, Fakih M, Strickler J, Desai J, Durm G, Shapiro G . KRAS Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020; 383(13):1207-1217. PMC: 7571518. DOI: 10.1056/NEJMoa1917239. View

18.

Le X, Paz-Ares L, Meerbeeck J, Viteri S, Galvez C, Smit E . Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B. Cell Rep Med. 2023; 4(11):101280. PMC: 10694660. DOI: 10.1016/j.xcrm.2023.101280. View

19.

Skoulidis F, Li B, Dy G, Price T, Falchook G, Wolf J . Sotorasib for Lung Cancers with p.G12C Mutation. N Engl J Med. 2021; 384(25):2371-2381. PMC: 9116274. DOI: 10.1056/NEJMoa2103695. View

20.

Manolakos P, Ward L . A Critical Review of the Prognostic and Predictive Implications of and Mutations and Co-Mutations in Metastatic Non-Small Lung Cancer. J Pers Med. 2023; 13(6). PMC: 10304809. DOI: 10.3390/jpm13061010. View